Detection of Molecular Signatures of Homologous Recombination Deficiency in Prostate Cancer with or without BRCA1/2 Mutations.
Zsófia M SztupinszkiMiklos DiossyMarcin KrzystanekJudit BörcsökMark M PomerantzViktoria TiszaSandor SpisakOrsolya RuszIstván CsabaiMatthew L FreedmanZoltan SzallasiPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2020)
These findings may expand the number of cases likely to respond to PARP inhibitor treatment. On the basis of the HR-associated mutational signatures, 5% to 8% of localized prostate cancer cases may be good candidates for PARP-inhibitor treatment (including those with BRCA1/2 mutations).